Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3b, Randomized, Open-Label, Double Crossover Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Adult Patients With IPSS R Intermediate Myelodysplastic Syndrome, Low Blast Acute Myeloid Leukemia, IPSS Intermediate-2 or High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

NCT05883956 is registered in ClinicalTrials.gov with Otsuka Australia Pharmaceutical Pty Ltd as lead sponsor.

NCT NCT05883956
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05883956 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3b, Randomized, Open-Label, Double Crossover Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Adult Patients With IPSS R Intermediate Myelodysplastic Syndrome, Low Blast Acute Myeloid Leukemia, IPSS Intermediate-2 or High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Lead sponsor
Otsuka Australia Pharmaceutical Pty Ltd
Phase
Phase 3
Overall status
Active, not recruiting
Start date
December 20, 2023
Completion date
May 31, 2025
Enrollment
13 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

leukemia, myeloid, acute, leukemia, myelomonocytic, chronic, myelodysplastic syndromes, patient preference